The CEO of Navidea Biopharmaceuticals, Jed Latkin, has resigned. Latkin and the company are discussing the terms of a severance agreement pursuant to his employment contract.
Three members of the company's board of directors will take over leadership while an executive search firm identifies the next CEO, the company said.
Latkin replaced former CEO Dr. Michael Goldberg in 2018 when Goldberg resigned.
